Osteotech and GenSci in patent tug of war:
This article was originally published in Clinica
Executive Summary
Osteotech has filed a patent infringement lawsuit against GenSci Labs and GenSci Regeneration Sciences, accusing the two companies of using its Grafton DBM process without permission nor licence. GenSci subsequently filed a suit against Osteotech, accusing it of infringing two of GenSci's patents by the processing the Grafton DBM Flex.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.